SPECTRAL-SPATIAL HETEROGENEITY FOR BREAST TUMOR CHARACTERIZATION

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 最近，在乳腺组织中发现了可能具有病理学特异性的近红外光谱吸收特征。这些光谱被称为“特定肿瘤成分”，或STC光谱，已被证明可以区分乳腺良恶性病变。在这项先前的工作中，肿瘤的STC光谱被平均在一起以提供肿瘤STC。然而，众所周知，肿瘤在结构和功能上是不同的。 我们认为，在给定的组织体积内，STC光谱的异质性可能指示肿瘤内不同细胞群体的空间分布。因此，表征光谱异质性的类型可能会预测肿瘤对治疗干预的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Recently NIR spectral absorption signatures that may be specific to pathology in breast tissues have been discovered. These spectra, referred to as "Specific Tumor Components", or STC spectra, have been shown to distinguish between benign and malignant breast lesions. In this previous work, STC spectra from tumors were averaged together to provide a tumor STC. However, tumors are known to be heterogeneous in structure and function. We propose that heterogeneity in the STC spectra within a given volume of tissue may be indicative of the spatial distribution of distinct cellular populations within the tumor. Characterizing the types of spectral heterogeneity might therefore predict the response of the tumor to therapeutic interventions.